Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5278715 | 0.88 | RAB9A (0.45) | RAB9AHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL5278052 | 0.88 | ATM (0.57) | ITGB3ITGA2BHTTMAPK1HDAC1 | |
| SCHEMBL5287500 | 0.86 | RAB9A (0.43) | RAB9AHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL5287408 | 0.85 | RAB9A (0.47) | RAB9AHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL5286752 | 0.85 | RAB9A (0.47) | RAB9AHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL5280483 | 0.84 | RAB9A (0.48) | RAB9ALMNAKMT2AHPGD | |
| SCHEMBL6037902 | 0.83 | RAB9A (0.50) | RAB9ALMNAKMT2AHPGD | |
| SCHEMBL5287584 | 0.83 | RAB9A (0.45) | RAB9AHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL5278754 | 0.83 | RAB9A (0.45) | RAB9AHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL5278625 | 0.81 | ASAH1 (0.54) | HTTHDAC1HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | disclosed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | ITGB3 2934/4885ITGA2B 3000/4885HTT 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.